** Genetics testing firm Tempus AI's shares TEM.O fall 8.2% to $67.75
** Stifel cuts to "hold" from "buy"; raises price target to $65 from $45
** Brokerage says the valuation of stock looks stretched, after company commentary suggested 2025 outlook for core business might be guided below Street expectations
** Brokerage says co's acquisition of Ambry Genetics will be positive to overall business
** But it expects TEM's revenue growth to slow, especially in the data segment; points to the slower growth profile of Ambry's hereditary cancer testing market
** Avg rating of brokerages is a "buy"; median PT is $52 - LSEG data
** As of last close, TEM has risen 84.3% since its June 14 debut on Nasdaq
(Reporting by Sukriti Gupta in Bengaluru)
((Sukriti.Gupta@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。